Background: Mixed hepatocellular and cholangiocarcinoma (HCC-CC) have been associated with a poor prognosis after liver transplantation (LT). We aimed to evaluate long-term outcomes in patients
Introduction
Mixed hepatocellular and cholangiocarcinoma (HCC-CC) comprise a minority of primary liver malignancies with histological features of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC). 1 The first histological classification of mixed HCC-CC was made by Allen et al. and included 3 types: type A for separate nodules of HCC and intrahepatic cholangiocarcinoma (ICC), type B for contiguous masses that may mingle with continued growth, and type C for those HCC and CC that are combined within the same tumor. 2 A second classification was formulated later on by Goodman et al., including type I for HCC and ICC coincidental occurrence as separate nodules, type II for Transitional Tumors, and type III for the Fibromellar HCC variant. 3 While mixed HCC-CCs have been reported to be more common in male patients and those with cirrhosis and/or chronic hepatitis, [4] [5] [6] their clinical behavior remains poorly understood. Although some authors have described that imaging showing contrast enhancement in the arterial and portal venous phases without washout could suggest the presence of HCC-CC, 7 others have reported that these tumors may share characteristics of both CC and HCC but with enhancement pattern and ancillary features similar to CC. 6 These tumors may be associated with higher carbohydrate antigen (CA) 19-9 and alpha-fetoprotein levels. 8 Therefore, distinguishing between HCC-CC, HCC, and CC continues to be a challenge without biopsy, and malignancies other than HCC are still encountered typically unexpectedly in explanted liver specimens. The mainstay of treatment for HCC-CC has been liver resection with most series reporting a 3-year survival rate of 25-50%. 1, 9 HCC is now a primary indication for liver transplantation (LT) in properly selected patients, where a 70% overall survival can be obtained. Recently, there has been increasing interest in determining the usefulness of liver transplantation (LT) for the treatment of select CC. The reported 5-year overall survival (OS) rate using LT to treat early-stage unresectable hilar CC ranges from 79% for patients with underlying primary sclerosing cholangitis (PSC) to 63% for those with de novo CC. 10 Unfortunately, only a small number of studies have been published to date regarding the use of LT for mixed HCC-CC. These studies have been limited by small sample sizes precluding meaningful conclusions. Chan et al. were the first known to report on LT for mixed HCC-CC on 3 patients, 2 of them alive with no evidence of disease 25 and 35 months after the procedure, respectively.
11
Panjala et al. reported the largest single-institution series including 12 patients undergoing LT for HCC-CC. Among this cohort, 1 patient died 48 days after the procedure from LTrelated complications and the median overall survival of the remaining patients was 3.6 years.
12
The prognosis of HCC-CC compared with HCC and CC has not been established, with most reports showing slightly worse prognosis with intermediate survival. The United Network for Organ Sharing (UNOS) has no formal statement regarding the use of LT for mixed HCC-CC, and to our knowledge only one previous publication has used this database to describe outcomes for patients with HCC-CC who underwent liver transplantation. 13 Hence, the aim of our study was to determine longterm outcomes of patients undergoing LT for mixed HCC-CC in the United States and to compare them to transplanted patients diagnosed with HCC and CC alone.
Methods
The UNOS database was queried for all patients undergoing transplantation in the United States from October The mean (SD) age of the patients undergoing transplantation for HCC-CC was 57 ± 10 years and 79 patients (74.7%) were male. Seventy-nine patients (74.5%) were white, 11 (10.6%) were black, 11 (10.6%) were hispanic and 3 (3.2%) were asian. The mean (SD) total bilirubin level was 2.96 (3.98) mg/dl, the mean (SD) international normalized ratio was 1.32 (0.31), the mean (SD) creatinine level was 0.97 (0.35) mg/dl, and the mean (SD) sodium level was 138 (4) mEq/L. The mean (SD) BMI was 28.1 (3.98) kg/m 2 . The median days on waiting list were 61. None of the patients undergoing LT for HCC-CC had multi-organ transplantation. Six patients (6.3%) underwent living donor LT. Six (6.3%) of the tumors were reported as incidentally found. The mean (SD) post transplantation length of stay was 9.8 (4.7) days. Table 1 summarizes patient characteristics for those who underwent LT for HCC-CC, HCC, and CC. The mean (SD) donor age was 40 ± 19 years and did not significantly differ between patients undergoing LT for HCC-CC and those undergoing LT for HCC and CC. The mean (SD) cold ischemic time was 7.2 ± 3.1 h, and the mean (SD) warm ischemic time was 10.2 ± 6.8 min Table 2 summarizes donors characteristics.
Results

From
Two patients who underwent LT for HCC-CC have previous history of other malignancies: one with meningioma and one with prostate cancer. Hepatitis C virus was the most common secondary diagnosis within the HCC-CC (44%) and HCC (36%) cohorts, compared to primary sclerosing cholangitis (PSC) in the CC (16%) cohort. Alcoholic cirrhosis was the second most common secondary diagnosis within the three groups (HCC-CC 9%, HCC 9%, and CC 2%). Other secondary diagnoses are presented in Table 3 .
The incidence of acute cellular rejection within 6 months after transplantation was 19%, 12.7%, and 22.4%, for those patients undergoing LT for HCC-CC, HCC, and CC, respectively.
Patient and graft survival
Overall, 1-, 3-, and 5-year OS rates were 82%, 47%, 40% respectively, in patients undergoing isolated LT for HCC-CC; with a median OS duration of 29 months (Fig. 2A) . Overall survival at 1-, 3-and 5-year for HCC-CC was similar to CC (79%, 58%, 47%) but significantly worse compared to HCC (86%, 72%, and 62% p = 0.002) (Fig. 2B) . Recurrence rate at 3 years for 27 patients with HCC-CC were information was available was 93%.
Graft survival at 1-, 3-, and 5-year, for HCC-CC (78%, 45%, 38%) was similar to CC (75%, 55%, 44%) but significantly worse than HCC (82%, 68%, 54%, p = 0.006) (Fig. 2C) . On Cox Regression analysis, no other factors (e.g. age, gender, any secondary diagnosis or waiting-time) were predictors of OS in patients undergoing LT for HCC-CC.
Discussion
In the United States, there are approximately 6000 LTs performed each year, and more than 70% of recipients now survive for at least 5 years at most centers.
14 Malignancy as a primary indication for LT increased from 7.7% in 2002 to 22.4% in 2012. 15, 16 Liver transplantation for HCC has evolved over the last several decades. Patients within Milan criteria have an overall survival rate of 86% and 62% at 1-and 5-year, respectively; equivalent to those patients undergo LT without primary liver malignancy. Due to the increasing incidence of mixed HCC-CC and the scarcity of reports in the setting of LT, our group was interested in determining the long-term outcome of patients undergoing LT for mixed HCC-CC and compared them with those patients undergoing transplantation for HCC and CC.
Cholangiocarcinoma represents approximately 10% of primary hepatobiliary malignancies. 17 Based on their location within the biliary tree, three different types have been described: intrahepatic cholangiocarcinoma (ICC), perihilar cholangiocarcinoma (PHC), and distal cholangiocarcinoma (DCC). 18 Resection for potential cure can be offered to less than 20% of patients with a reported 5-year survival of 20-30%. 10 Lymph node invasion, bilateral liver involvement, and vascular encasement frequently preclude potentially curative resection. While LT was once thought to be an ideal operation for ICC, several multicenter series demonstrate low 3 and 5-year patient survival (20-30%) and high recurrence rates (50-60%) with liver transplant alone. [19] [20] [21] During the last decade, LT (in combination with neoadjuvant therapy and operative staging) has achieved remarkable success for appropriate selected patients with earlystage unresectable PHC, with an overall 5-year survival up to 73% and recurrence rate of 18%. 10 Factors associated with recurrence included age above 45 years old, high CA 19-9 levels and tumor size. 22 We found 1-, 3-and 5-year overall survival rates of 79%, 58%, and 47%, respectively; in patients undergoing LT for CC. We should consider that UNOS database does not distinguish between ICC and PHC within the CC diagnosis. According to limited reports, HCC-CC represents less than 5% of all liver cancers, 23, 24 and although CC and HCC may develop distantly in the liver, the majority of the HCC-CC specimens appear to be transitional tumor subtypes. It has been described that HCC-CC clinicopathologic characteristics include more frequent multifocal lesions, as well as more microvascular emboli, portal vein and lymph node invasion 25 ;
which perhaps could explain the relative poor prognosis associated with this type of tumor. [1] [2] [3] [4] [5] [6] [7] [8] [9] To best of our knowledge, this study analyzed the largest series of patients undergoing LT for HCC-CC in the United States. HPB had a mean age at transplant of 57 years and 74.7% were male, in congruence with previous reports. [4] [5] [6] Patients in the CC group were found to have higher serum bilirubin levels (mean 7.26 mg/ dl), when compared to those within the HCC-CC (mean 2.96 mg/dl) and HCC (mean 3.86 mg/dl) groups (p < 0.001). However, laboratory MELD score did not significantly differ between the three groups and the majority had a MELD score lower than 15. This finding supports that most of these patients were transplanted with MELD exception. The percentage of HCC-CC reported as being incidentally found was low (6.3%), even though the lab MELD score at time of transplant was low. We believe this is because the majority of these patients were thought to have HCC prior to transplant but were found to have HCC-CC on explant so the true percentage of incidental finding of HCC-CC is probably not reflective in this percentage.
We identified hepatitis C and alcoholic cirrhosis as the most common secondary diagnosis in patients undergoing LT for HCC-CC, 44% and 9% respectively; similar to those patients with HCC. This suggests that the presence of HCC-CC is frequently complicated by chronic parenchymal liver disease, as previous reports have described. 9 It is not surprising therefore, that resection for HCC-CC can be considered difficult in a majority of cases. Only 2% of patients within the HCC-CC group were reported to have primary sclerosing cholangitis (PSC), differing from those patients transplanted for CC in which it is the most common secondary diagnosis (16%). This finding supports the relevance of PSC as a known risk factor for the development of CC.
18,21
Patients with HCC-CC who are unresectable rarely survive more than 2 years. While poor survival after resection has been reported previously, data on outcomes after LT for this type of tumor is very limited.
7,12,13 Jarnagin et al. assessed outcomes in 27 patients with HCC-CC. Seventy-eight percent of them underwent resection with a 5-year survival of 24%, not significantly different compared to that in the CC and HCC cohort, 33% and 37% respectively. Notably, all patients with HCC-CC that were not amenable to resection died within 18 months. 10 Liu et al.
retrospectively analyzed 10 patients with HCC-CC who underwent resection in their center with similar clinicopathological characteristics when compared with patients with HCC and ICC. The overall survival was 17 months for the HCC-CC group, similar to the CC group (26 months), but significantly worse than that of the HCC group (52 months). 9 Zhan et al. evaluated prognostic features of 27 patients with combined HCC-CC that underwent either liver resection or LT. In all cases, diagnosis was performed by postoperative biopsies. Twenty-five patients underwent hepatic resection and three received LT. Mean follow-up was 25.8 months with overall survival rates at 1-and 2-year of 72.5 and 49.4%, and disease-free survival rates at 1-and 2-year of 54.2 and 41.3%, respectively. 24 Park et al. performed a retrospective study of 15 patients who underwent LT for pathologically confirmed HCC-CC with a pretransplant diagnosis of HCC over a period of 10 years. Seven patients experienced tumor recurrence. The overall survival rates were 66.7%, 60%, and 60% at 1-, 3-, and 5-year, respectively; while disease-free survival rates were 60% at 1 year and 53.3% at 3-and 5-year, respectively. 26 Recently, Groeschl et al. performed a retrospective analysis of the Surveillance, epidemiology and end results (SEER) database comparing the survival of mixed HCC-CC and HCC patients undergoing both LT and hepatic resection. Their results showed that patients undergoing LT for HCC have a significantly longer survival compared to patients with HCC-CC (68 months vs. 36 months), with a 3 year survival rate of 78% in the HCC group compared to 48% in the HCC-CC counterpart. The authors inquired clinical characteristics and survival data of patients with a pathologic diagnosis of HCC-CC from UNOS Database up to October, 2011. Their analysis included 65 patients transplanted for HCC-CC since 1994, with a median age of 55 years and overall 1-, 3-, and 5-year patient survival of 75%, 45%, and 28%, respectively. In this report, the authors did not compared outcomes in between patients undergoing LT for HCC-CC, HCC, and CC. 13 Over our study period patients undergoing LT for HCC-CC had an overall 1-, 3-, and 5-year survival rate of 82%, 47%, and 40%, respectively; with a median survival time of 29 months. In accordance to previous reports, 13 patients undergoing LT for HCC had significantly better survival at the same time points (86%, 72%, and 62%) compared to those transplanted for HCC-CC and CC. LT for mixed HCC-CC confers a survival rate similar to carefully selected patients that underwent LT for CC in UNOS database. Similarly, graft survival rate was significantly better within the HCC group (82%, 68%, 54% at 1-, 3-, and 5-year) when compared to those in the HCC-CC and CC cohort. Interestingly, acute rejection rate at 6 months was higher in patients with CC (22.4%) when compared with those with HCC-CC (19%) and HCC (12.7%). Our study has some limitations that we should address. This was a retrospective analysis of the UNOS database, which was not developed to study cancer population. The absence of a specific HCC-CC diagnosis in the UNOS database could lead to selection bias. Key variables were not captured including tumor characteristics (eg, tumor size, location, number, percentage of liver parenchyma involved with tumor, vascular invasion and cell differentiation), pre-and post-transplantation treatments, and pre-transplantation imaging used to determine the diagnosis and extent of the disease. We were unable to find differences in the frequency, features and outcomes of HCC-CC subtypes. Additionally, recurrence data was not available for the vast majority of the study population. Despite these limitations, the strength of our study comes not only from the large number of patients with HCC-CC included in the database, but also from its clinically robust definitions of patient characteristics.
In conclusion, our results demonstrate that patients undergoing LT for HCC have better overall survival from those with HCC-CC and CC. Outcomes of HCC-CC may more closely follow the CC phenotype. We believe that early diagnosis of mixed HCC-CC is essential for a potential cure. As the experience in LT for HCC-CC is very limited, controversial issues which arise in our study include the following questions. How can mixed HCC-CC be best diagnosed definitively prior to liver transplantation? If unresectable, what is the role of LT in HCC-CC treatment? Would transplantation with neoadjuvant therapy be better treatment than resection, even for patients with potentially resectable disease? Attempts should be made to identify HCC-CC patients prior to transplantation and to better understand predictors of outcomes, which could help to standardize selection criteria. Future studies should also address special consideration for immunosuppression modification and/ or adjuvant therapy in those patients found to have HCC-CC on explanted specimens.
